Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID	DTD0010 Transporter Info
Gene Name	SLC22A1
Transporter Name	Organic cation transporter 1
Gene ID	6580
UniProt ID	O15245

Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)
Chemical Compound
DT Modulation1	Quinine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Quinine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Quinine inhibits the reaction SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Quinine results in decreased activity of SLC22A1			[69]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Quinine results in decreased activity of SLC22A1 protein			[77]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Quinine results in decreased activity of SLC22A1 which results in decreased uptake of abacavir			[69]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	SLC22A1 protein results in increased uptake of Quinine			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	4-biphenylamine inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[29]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	bisphenol A inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	bisphenol F inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	bisphenol S promotes the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Imipramine inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[84]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Nicotine inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[29]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	SLC22A1 protein affects the transport of Tetraethylammonium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	SLC22A1 protein results in increased import of Tetraethylammonium			[96]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	SLC22A1 protein results in increased uptake of Tetraethylammonium			[97]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	SLC22A1 results in increased import of Tetraethylammonium			[66]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	tetrabromobisphenol A inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation14	Tetraethylammonium inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation15	Tetraethylammonium inhibits the reaction SLC22A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation16	Tetraethylammonium inhibits the reaction SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation17	Tetraethylammonium inhibits the reaction SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation18	Tobacco Smoke Pollution inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[29]
Regulation Mechanism				Transcription Factor Info
DT Modulation19	Verapamil inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[96]
Regulation Mechanism				Transcription Factor Info
DT Modulation20	Verapamil inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Verapamil inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[96]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Verapamil inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Verapamil inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Verapamil inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Estradiol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Estradiol results in decreased activity of SLC22A1 protein			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Estradiol results in decreased expression of SLC22A1 mRNA			[73]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Ranitidine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Ranitidine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC22A1 protein affects the transport of Ranitidine			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Clonidine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Cimetidine inhibits the reaction SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Prazosin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Prazosin results in decreased activity of SLC22A1 protein			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Phenoxybenzamine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Phenoxybenzamine results in decreased activity of SLC22A1 protein			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Progesterone inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Progesterone results in decreased activity of SLC22A1 protein			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Amitriptyline inhibits the reaction SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Amitriptyline results in decreased activity of SLC22A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Famotidine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC22A1 protein affects the transport of Famotidine			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Atropine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Atropine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	NCOA1 protein inhibits the reaction NR1I2 protein co-treated with Rifampin results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	NCOA1 protein inhibits the reaction NR1I2 protein results in increased susceptibility to Rifampin which results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	NR1I2 protein co-treated with Rifampin results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	NR1I2 protein results in increased susceptibility to Rifampin which results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Rifampin inhibits the reaction NCOA1 protein binds to SLC22A1 promoter			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Rifampin promotes the reaction NR1I2 protein results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Rifampin results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Rifampin results in decreased expression of SLC22A1 protein			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Diphenhydramine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Etilefrine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Dieldrin results in decreased activity of SLC22A1 protein			[27]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Atenolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Chloroquine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Cyclosporine results in decreased expression of SLC22A1 mRNA			[73]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Diclofenac results in decreased activity of SLC22A1 protein			[39]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Digoxin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Diltiazem inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Folic Acid deficiency results in decreased expression of SLC22A1 mRNA			[82]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Imipramine inhibits the reaction SLC22A1 protein results in increased uptake of Metformin			[84]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Imipramine inhibits the reaction SLC22A1 protein results in increased uptake of Quercetin			[85]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Imipramine inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[84]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Ketoprofen results in decreased activity of SLC22A1 protein			[39]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Lidocaine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Metoprolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Propafenone inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Propranolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Spironolactone inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Sulindac results in decreased activity of SLC22A1 protein			[39]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Trimethoprim inhibits the reaction SLC22A1 protein results in increased uptake of Quercetin			[85]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Troglitazone results in decreased expression of SLC22A1 mRNA			[98]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Valproic Acid results in decreased expression of SLC22A1 mRNA			[99]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Indomethacin results in decreased activity of SLC22A1 protein			[39]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Mefenamic Acid results in decreased activity of SLC22A1 protein			[39]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Carvedilol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Dexamethasone results in increased expression of SLC22A1 mRNA			[81]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Dexamethasone results in increased expression of SLC22A1 protein			[81]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Heptachlor results in decreased activity of SLC22A1 protein			[27]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Chlordan results in decreased activity of SLC22A1 protein			[27]
Regulation Mechanism				Transcription Factor Info
DT Modulation1	Benzo(a)pyrene affects the methylation of SLC22A1 promoter			[76]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Benzo(a)pyrene results in decreased activity of SLC22A1 protein			[77]
Regulation Mechanism				Transcription Factor Info
1-Methyl-4-phenylpyridinium	51 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-Methyl-4-phenylpyridinium inhibits the reaction SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Amiodarone inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	artemisinin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Atenolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Atorvastatin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Atropine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Atropine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Bisoprolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Carvedilol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Chloroquine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation11	Clonidine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation12	Digoxin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation13	Diltiazem inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation14	diosmetin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[61]
Regulation Mechanism				Transcription Factor Info
DT Modulation15	Diphenhydramine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation16	Estradiol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation17	Etilefrine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation18	Famotidine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation19	Flecainide inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation20	Ipratropium inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation21	Lidocaine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation22	Mefloquine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation23	Metformin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation24	Metoprolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation25	Molsidomine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation26	Monocrotaline inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation27	MYC protein results in increased expression of SLC22A1 protein which results in increased import of 1-Methyl-4-phenylpyridinium			[63]
Regulation Mechanism				Transcription Factor Info
DT Modulation28	Nadolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation29	Nifedipine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation30	Phenoxybenzamine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation31	Prazosin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation32	Progesterone inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation33	Propafenone inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation34	Propranolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation35	pseudoisocyanine affects the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation36	pseudoisocyanine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation37	Pyrimethamine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation38	Quinidine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation39	Quinine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation40	Quinine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
DT Modulation41	Ranitidine inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation42	Ranitidine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation43	SLC22A1 protein results in increased import of 1-Methyl-4-phenylpyridinium			[65]
Regulation Mechanism				Transcription Factor Info
DT Modulation44	SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[2]
Regulation Mechanism				Transcription Factor Info
DT Modulation45	SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation46	SLC22A1 results in increased import of 1-Methyl-4-phenylpyridinium			[66]
Regulation Mechanism				Transcription Factor Info
DT Modulation47	Spironolactone inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation48	talinolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
DT Modulation49	Tetraethylammonium inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation50	Verapamil inhibits the reaction SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation51	Verapamil inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
2-amino-3,4-dimethylimidazo(4,5-f)quinoline	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-amino-3,4-dimethylimidazo(4,5-f)quinoline inhibits the reaction SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	2-amino-3,4-dimethylimidazo(4,5-f)quinoline results in decreased activity of SLC22A1 protein			[54]
Regulation Mechanism				Transcription Factor Info
3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine inhibits the reaction SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine results in decreased activity of SLC22A1 protein			[54]
Regulation Mechanism				Transcription Factor Info
3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole inhibits the reaction SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole results in decreased activity of SLC22A1 protein			[54]
Regulation Mechanism				Transcription Factor Info
3-amino-1-methyl-5H-pyrido(4,3-b)indole	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	3-amino-1-methyl-5H-pyrido(4,3-b)indole inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	3-amino-1-methyl-5H-pyrido(4,3-b)indole results in decreased activity of SLC22A1 protein			[54]
Regulation Mechanism				Transcription Factor Info
4-(4-dimethylaminostyryl)-1-methylpyridinium	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-(4-dimethylaminostyryl)-1-methylpyridinium inhibits the reaction SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	SLC22A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Tetraethylammonium inhibits the reaction SLC22A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium			[68]
Regulation Mechanism				Transcription Factor Info
4-biphenylamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-biphenylamine inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[29]
Regulation Mechanism				Transcription Factor Info
abacavir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Quinine results in decreased activity of SLC22A1 which results in decreased uptake of abacavir			[69]
Regulation Mechanism				Transcription Factor Info
abrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	abrine results in increased expression of SLC22A1 mRNA			[70]
Regulation Mechanism				Transcription Factor Info
acetamiprid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	acetamiprid results in increased activity of SLC22A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
Amiodarone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amiodarone inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
aristolochic acid I	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	aristolochic acid I results in increased expression of SLC22A1 mRNA			[75]
Regulation Mechanism				Transcription Factor Info
artemisinin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	artemisinin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
Atazanavir Sulfate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
beta-Naphthoflavone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	beta-Naphthoflavone results in decreased expression of SLC22A1 mRNA			[50]
Regulation Mechanism				Transcription Factor Info
Bisoprolol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisoprolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
bisphenol A	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol A inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	bisphenol A results in decreased activity of SLC22A1 protein			[52]
Regulation Mechanism				Transcription Factor Info
bisphenol F	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol F inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
bisphenol S	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	bisphenol S promotes the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
CGP 52608	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	CGP 52608 promotes the reaction RORA protein binds to SLC22A1 gene			[78]
Regulation Mechanism				Transcription Factor Info
Chenodeoxycholic Acid	10 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chenodeoxycholic Acid results in decreased expression of SLC22A1 mRNA			[79]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Tartrazine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
DT Modulation10	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
Deoxycholic Acid	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Tartrazine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
diosmetin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	diosmetin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[61]
Regulation Mechanism				Transcription Factor Info
Ethidium	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	1-Methyl-4-phenylpyridinium inhibits the reaction SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Cimetidine inhibits the reaction SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Quinine inhibits the reaction SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Tetraethylammonium inhibits the reaction SLC22A1 protein results in increased uptake of Ethidium			[59]
Regulation Mechanism				Transcription Factor Info
Flecainide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Flecainide inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
Fonofos	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fonofos results in increased methylation of SLC22A1 promoter			[83]
Regulation Mechanism				Transcription Factor Info
Glycochenodeoxycholic Acid	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Tartrazine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
Glycocholic Acid	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Tartrazine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
Glycodeoxycholic Acid	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	Tartrazine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
harman	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	harman inhibits the reaction SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	harman results in decreased activity of SLC22A1 protein			[54]
Regulation Mechanism				Transcription Factor Info
Hexachlorocyclohexane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hexachlorocyclohexane results in decreased activity of SLC22A1 protein			[27]
Regulation Mechanism				Transcription Factor Info
hyperforin	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	hyperforin promotes the reaction NR1I2 protein results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	hyperforin results in decreased expression of SLC22A1 protein			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	NR1I2 protein co-treated with hyperforin results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	NR1I2 protein results in increased susceptibility to hyperforin which results in decreased expression of SLC22A1 mRNA			[49]
Regulation Mechanism				Transcription Factor Info
Ipratropium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ipratropium inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
Lamivudine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC22A1 protein results in increased uptake of Lamivudine			[86]
Regulation Mechanism				Transcription Factor Info
Mefloquine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mefloquine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	methyleugenol results in decreased expression of SLC22A1 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
Molsidomine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Molsidomine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
Monocrotaline	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Monocrotaline inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Quinidine inhibits the reaction SLC22A1 protein results in increased uptake of Monocrotaline			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC22A1 protein results in increased uptake of Monocrotaline			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	tetrahydropalmatine inhibits the reaction SLC22A1 protein results in increased uptake of Monocrotaline			[62]
Regulation Mechanism				Transcription Factor Info
N(1)-methylnicotinamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC22A1 results in increased import of N(1)-methylnicotinamide			[66]
Regulation Mechanism				Transcription Factor Info
Nadolol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nadolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
nefazodone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
Nicotine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nicotine inhibits the reaction SLC22A1 protein results in increased import of Tetraethylammonium			[29]
Regulation Mechanism				Transcription Factor Info
Nifedipine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nifedipine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
nitenpyram	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	nitenpyram results in increased activity of SLC22A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
N-Nitrosopyrrolidine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	N-Nitrosopyrrolidine results in decreased expression of SLC22A1 mRNA			[56]
Regulation Mechanism				Transcription Factor Info
norharman	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	norharman inhibits the reaction SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide			[54]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	norharman results in decreased activity of SLC22A1 protein			[54]
Regulation Mechanism				Transcription Factor Info
nuciferine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	nuciferine inhibits the reaction SLC22A1 protein results in increased uptake of Metformin			[87]
Regulation Mechanism				Transcription Factor Info
Okadaic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Okadaic Acid results in decreased expression of SLC22A1 mRNA			[89]
Regulation Mechanism				Transcription Factor Info
o,p'-DDT	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	o,p'-DDT results in decreased expression of SLC22A1 mRNA			[27]
Regulation Mechanism				Transcription Factor Info
Ozone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Air Pollutants results in increased abundance of Ozone which affects the expression of SLC22A1 mRNA			[90]
Regulation Mechanism				Transcription Factor Info
Parathion	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Parathion results in increased methylation of SLC22A1 promoter			[83]
Regulation Mechanism				Transcription Factor Info
perfluorobutanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorobutanesulfonic acid results in increased expression of SLC22A1 mRNA			[91]
Regulation Mechanism				Transcription Factor Info
perfluorodecanesulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorodecanesulfonic acid results in increased expression of SLC22A1 mRNA			[91]
Regulation Mechanism				Transcription Factor Info
perfluorooctane sulfonic acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctane sulfonic acid results in decreased expression of SLC22A1 mRNA			[57]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	perfluorooctane sulfonic acid results in increased expression of SLC22A1 mRNA			[91]
Regulation Mechanism				Transcription Factor Info
perfluorooctanoic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluorooctanoic acid results in increased expression of SLC22A1 mRNA			[91]
Regulation Mechanism				Transcription Factor Info
pirinixic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	pirinixic acid binds to and results in increased activity of PPARA protein which results in decreased expression of SLC22A1 mRNA			[92]
Regulation Mechanism				Transcription Factor Info
pseudoisocyanine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	pseudoisocyanine affects the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[64]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	pseudoisocyanine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[13]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	pseudoisocyanine results in decreased activity of SLC22A1 protein			[13]
Regulation Mechanism				Transcription Factor Info
Pyrimethamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pyrimethamine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[60]
Regulation Mechanism				Transcription Factor Info
Quinidine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Quinidine inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Quinidine inhibits the reaction SLC22A1 protein results in increased uptake of Monocrotaline			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Quinidine inhibits the reaction SLC22A1 protein results in increased uptake of Quercetin			[85]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Quinidine inhibits the reaction SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
retrorsine	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-(4-dimethylaminostyryl)-1-methylpyridinium inhibits the reaction SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Quinidine inhibits the reaction SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC22A1 protein promotes the reaction CYP3A4 protein results in increased susceptibility to retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation5	Tetraethylammonium inhibits the reaction SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	tetrahydropalmatine inhibits the reaction SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
S-(1,2-dichlorovinyl)cysteine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	S-(1,2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides which results in increased expression of SLC22A1 mRNA			[93]
Regulation Mechanism				Transcription Factor Info
Silicon Dioxide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Silicon Dioxide analog results in increased expression of SLC22A1 mRNA			[94]
Regulation Mechanism				Transcription Factor Info
sodium arsenite	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	sodium arsenite results in decreased expression of SLC22A1 mRNA			[53]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	sodium arsenite results in increased expression of SLC22A1 mRNA			[95]
Regulation Mechanism				Transcription Factor Info
talinolol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	talinolol inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
Tartrazine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Tartrazine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
terbufos	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	terbufos results in increased methylation of SLC22A1 promoter			[83]
Regulation Mechanism				Transcription Factor Info
tetrabromobisphenol A	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tetrabromobisphenol A inhibits the reaction SLC22A1 protein results in increased uptake of Tetraethylammonium			[52]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	tetrabromobisphenol A results in decreased activity of SLC22A1 protein			[52]
Regulation Mechanism				Transcription Factor Info
Tetrachlorodibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetrachlorodibenzodioxin results in decreased expression of SLC22A1 mRNA			[73]
Regulation Mechanism				Transcription Factor Info
tetrahydropalmatine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	tetrahydropalmatine inhibits the reaction SLC22A1 protein results in increased uptake of Monocrotaline			[62]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	tetrahydropalmatine inhibits the reaction SLC22A1 protein results in increased uptake of retrorsine			[68]
Regulation Mechanism				Transcription Factor Info
thiacloprid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	thiacloprid metabolite results in increased activity of SLC22A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	thiacloprid results in increased activity of SLC22A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
Triclosan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Triclosan co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid results in decreased expression of SLC22A1 mRNA			[80]
Regulation Mechanism				Transcription Factor Info
trospium chloride	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	SLC22A1 protein results in increased metabolism of trospium chloride			[67]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	trospium chloride results in decreased activity of SLC22A1 protein			[67]
Regulation Mechanism				Transcription Factor Info
Nanoparticle
perfluoro-n-nonanoic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	perfluoro-n-nonanoic acid results in decreased expression of SLC22A1 mRNA			[57]
Regulation Mechanism				Transcription Factor Info
Approved Drug
Quinine	14 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 6.7 microM)			[1]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation2	Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 13 microM)			[2]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation3	Quinine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 5.7 microM)			[3]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Chinese hamster ovary (CHO) cells-OCT1
DT Modulation4	Quinine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 22.9 microM)			[4]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
DT Modulation5	Quinine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 17.5 microM)			[4]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
DT Modulation6	Quinine inhibits the transportation of YM155 by SLC22A1 (IC50 = 7.11 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation7	Quinine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Verapamil	8 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Verapamil inhibits the transportation of Metformin by SLC22A1 (IC50 = 0.62 microM)			[10]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Verapamil inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2.9 microM)			[4]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
DT Modulation3	Verapamil inhibits the transportation of YM155 by SLC22A1 (IC50 = 1.23 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation4	Verapamil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Metformin	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Metformin inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1231 microM)			[1]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation2	Metformin inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 493 microM)			[11]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation3	Metformin inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2820 microM)			[11]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation4	Metformin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6], [12]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation5	Imipramine inhibits the reaction SLC22A1 protein results in increased uptake of Metformin			[84]
Regulation Mechanism				Transcription Factor Info
DT Modulation6	Metformin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[1]
Regulation Mechanism				Transcription Factor Info
DT Modulation7	nuciferine inhibits the reaction SLC22A1 protein results in increased uptake of Metformin			[87]
Regulation Mechanism				Transcription Factor Info
DT Modulation8	SLC22A1 protein results in increased susceptibility to Metformin			[88]
Regulation Mechanism				Transcription Factor Info
DT Modulation9	SLC22A1 protein results in increased uptake of Metformin			[84]
Regulation Mechanism				Transcription Factor Info
Estradiol	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 5.73 microM)			[13]
Affected Drug/Substrate	1-Methyl-4-phenylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Estradiol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation3	Estradiol inhibits the activity of SLC22A1			[13]
Repaglinide	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Repaglinide inhibits the transportation of Metformin by SLC22A1 (IC50 = 1.6 microM)			[14]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-OCT1
DT Modulation2	Repaglinide inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1.8 microM)			[14]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Madin Darby canine kidney strain II (MDCKII) cells-OCT1
DT Modulation3	Repaglinide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ranitidine	6 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 33 microM)			[1]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation2	Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 28 microM)			[2]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation3	Ranitidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Clonidine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clonidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 6.5 microM)			[2]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Clonidine inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 0.55 microM)			[4]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
DT Modulation3	Clonidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cimetidine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cimetidine inhibits the transportation of YM155 by SLC22A1 (IC50 = 149 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Cimetidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6], [12]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation3	Cimetidine inhibits the activity of SLC22A1			[11]
Prazosin	5 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Prazosin inhibits the transportation of YM155 by SLC22A1 (IC50 = 1.56 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Prazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation3	Prazosin inhibits the activity of SLC22A1			[13], [16]
Nicotine polacrilex	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nicotine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Nicotine inhibits the transportation of Tetraethylammonium by SLC22A1			[15]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
DT Modulation3	Nicotine inhibits the activity of SLC22A1			[17]
Vecuronium	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vecuronium inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (Ki = 120 microM)			[18]
Affected Drug/Substrate	1-Methyl-4-phenylpyridinium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation2	Vecuronium inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 232 microM)			[4]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Phenoxybenzamine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 2.72 microM)			[13]
Affected Drug/Substrate	1-Methyl-4-phenylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Phenoxybenzamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Progesterone	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1 (IC50 = 3.05 microM)			[13]
Affected Drug/Substrate	1-Methyl-4-phenylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Progesterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Disopyramide	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Disopyramide inhibits the transportation of 4-(4-Dimethylamino)styryl-N-methylpyridinium (ASP+) by SLC22A1 (IC50 = 81.7 microM)			[6]
Affected Drug/Substrate	4-(4-Dimethylamino)styryl-N-methylpyridinium (ASP+)	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Disopyramide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Amitriptyline	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amitriptyline inhibits the transportation of Metformin by SLC22A1 (IC50 = 6.99 microM)			[10]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Amitriptyline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Glyburide	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glibenclamide inhibits the transportation of Metformin by SLC22A1 (IC50 = 199 microM)			[10]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Glibenclamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Simvastatin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Simvastatin inhibits the transportation of Metformin by SLC22A1 (IC50 = 89 microM)			[10]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Simvastatin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Famotidine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Famotidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 28 microM)			[1]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation2	Famotidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Atropine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atropine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 1.2 microM)			[2]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Atropine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Amantadine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amantadine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 236 microM)			[20]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Amantadine inhibits the transportation of YM155 by SLC22A1 (IC50 = 39.6 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Memantine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Memantine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 3.7 microM)			[20]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Memantine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ritonavir	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ritonavir inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 14 microM)			[21]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Ritonavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 5.18 microM)			[22]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Acebutolol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acebutolol inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 95.8 microM)			[4]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
DT Modulation2	Acebutolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Indinavir	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Indinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 61.7 microM)			[22]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
DT Modulation2	Indinavir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Procainamide	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Procainamide inhibits the transportation of YM155 by SLC22A1 (IC50 = 51.3 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Procainamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Tubocurarine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tubocurarine inhibits the transportation of YM155 by SLC22A1 (IC50 = 62.4 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Tubocurarine inhibits the activity of SLC22A1			[23]
Pancuronium	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pancuronium inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A1			[18]
Affected Drug/Substrate	1-Methyl-4-phenylpyridinium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation2	Pancuronium inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Amiloride	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amiloride inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Amiloride inhibits the activity of SLC22A1			[23]
Rifampicin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rifampicin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Profenamine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ethopropazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[12]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Ethopropazine inhibits the transportation of Metformin by SLC22A1			[12]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Tacrine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tacrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[12]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Tacrine inhibits the transportation of Metformin by SLC22A1			[12]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Vitamin B1	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vitamin B1 inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[12]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Vitamin B1 inhibits the transportation of Tetraethylammonium by SLC22A1			[15]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Rifampin	9 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rifampicin induces the activity of SLC22A1			[24]
Pioglitazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pioglitazone inhibits the transportation of Metformin by SLC22A1 (IC50 = 185 microM)			[10]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Butylscopolamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Butylscopolamine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 16 microM)			[2]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Diphenhydramine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 3.4 microM)			[2]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cocaine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cocaine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 85 microM)			[20]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Dextroamphetamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dextroamphetamine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 202 microM)			[20]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ketamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ketamine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 114.5 microM)			[20]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Pentamidine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 16.4 microM)			[3]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Chinese hamster ovary (CHO) cells-OCT1
Midazolam	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Midazolam inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 3.7 microM)			[4]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Nelfinavir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nelfinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 21.8 microM)			[22]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Saquinavir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Saquinavir inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 8.26 microM)			[22]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Lindane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lindane inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 1.52 microM)			[27]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human hepatoma HepaRG cells-OCT1
Benzyl alcohol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzyl alcohol inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 0.018 microM)			[30]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Acarbose	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acarbose inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Acetaminophen	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acetaminophen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Acetaminophen results in decreased expression of SLC22A1 mRNA			[71]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen results in decreased expression of SLC22A1 mRNA			[72]
Regulation Mechanism				Transcription Factor Info
Acetylcysteine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acetylcysteine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Acyclovir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acyclovir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Allopurinol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Allopurinol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ampicillin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ampicillin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Amsacrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Amsacrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Apomorphine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Apomorphine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Aspirin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aspirin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Atenolol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atenolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Azathioprine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Azathioprine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Baclofen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Baclofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Budesonide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Budesonide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Buspirone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Buspirone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Caffeine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Caffeine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Candesartan	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Candesartan inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Captopril	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Captopril inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Carbamazepine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Carbamazepine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Carisoprodol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Carisoprodol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Celecoxib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Celecoxib inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cephalexin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cephalexin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cetirizine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cetirizine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Chloramphenicol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chloramphenicol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Chloroquine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chloroquine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Chlorpromazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlorpromazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Chlorprothixene	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlorprothixene inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Chlorzoxazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlorzoxazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Citalopram	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citalopram inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Clemastine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clemastine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Clindamycin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clindamycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Clodronic Acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clodronate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Clomipramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clomipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Clotrimazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clotrimazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Clozapine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Clozapine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Codeine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Codeine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Colchicine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Colchicine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cyclophosphamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cyclophosphamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cyclosporine	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cyclosporine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cyproterone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cyproterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cysteamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cysteamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Denopamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Denopamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Desipramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Desipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Diazepam	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Diazepam inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Diclofenac	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Diclofenac inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Digoxin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Digoxin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Diltiazem	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Diltiazem inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Dopamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dopamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Doxazosin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Doxazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Doxycycline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Doxycycline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Efavirenz	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Efavirenz inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Eflornithine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Eflornithine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Enalapril	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Enalapril inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ergotamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ergotamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ergotidine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ergotidine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Erythromycin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Erythromycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Esmolol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Esmolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Etoposide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Etoposide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Felodipine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Felodipine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Fenofibrate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fenofibrate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Fentanyl	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fentanyl inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Fluorouracil	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fluorouracil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Fluphenazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fluphenazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Flutamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Flutamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Folic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Folic acid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Furosemide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Furosemide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Gabapentin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Gabapentin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ganciclovir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ganciclovir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Glipizide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glipizide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Glucosamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Glucosamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Haloperidol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Haloperidol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Hydralazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hydralazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Hydrochlorothiazide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hydrochlorothiazide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ibuprofen	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ibuprofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Ibuprofen results in decreased activity of SLC22A1 protein			[39]
Regulation Mechanism				Transcription Factor Info
Imipramine	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Imipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ketoconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ketoconazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ketoprofen	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ketoprofen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Levodopa	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Levodopa inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Levofloxacin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Levofloxacin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Levothyroxine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Levothyroxine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Lidocaine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Lidocaine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Loperamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Loperamide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Loratadine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Loratadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Mannitol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mannitol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Meclizine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Meclizine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Mepenzolate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mepenzolate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Methimazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methimazole inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Methotrexate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methotrexate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Methyldopa	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methyldopa inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Metoclopramide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Metoclopramide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Metoprolol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Metoprolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Mianserin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mianserin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Morphine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Morphine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Naltrexone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Naltrexone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Nandrolone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Nandrolone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Ondansetron	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Ondansetron inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Orciprenaline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Orciprenaline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Orphenadrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Orphenadrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Oxprenolol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Oxprenolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Paclitaxel	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Paclitaxel inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Papaverine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Papaverine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Phenobarbital	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenobarbital inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Phenytoin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenytoin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Pilocarpine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pilocarpine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Pravastatin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pravastatin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Prednisone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Prednisone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Probenecid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Probenecid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Prochlorperazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Prochlorperazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Promazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Promazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Promethazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Promethazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Propafenone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Propafenone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Propofol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Propofol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Propranolol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Propranolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Risperidone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Risperidone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Scopolamine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Scopolamine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Sotalol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sotalol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Spironolactone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Spironolactone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Sulfasalazine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sulfasalazine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Sulindac	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sulindac inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Tamoxifen	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tamoxifen inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Terazosin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Terazosin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Terbutaline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Terbutaline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Tetracycline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetracycline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Theophylline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Theophylline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Timolol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Timolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Tramadol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tramadol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Trihexyphenidyl	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Trihexyphenidyl inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Trimethoprim	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Trimethoprim inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Trimipramine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Trimipramine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Troglitazone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Troglitazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Valproic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Valproic Acid inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Vancomycin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vancomycin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Vinblastine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Vinblastine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Warfarin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Warfarin inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Zanamivir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Zanamivir inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Zidovudine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Zidovudine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Dolutegravir	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dolutegravir inhibits the transportation of Metformin by SLC22A1			[31]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Caspofungin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Caspofungin inhibits the transportation of Tetraethyl by SLC22A1			[32]
Affected Drug/Substrate	Tetraethyl	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Pindolol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pindolol inhibits the transportation of Tetraethylammonium by SLC22A1			[15]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Rocuronium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rocuronium inhibits the transportation of Tributylmethylammonium by SLC22A1			[33]
Affected Drug/Substrate	Tributylmethylammonium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
Beclomethasone dipropionate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Beclomethasone dipropionate inhibits the transportation of Agonist salbutamol by SLC22A1			[35]
Affected Drug/Substrate	Agonist salbutamol	Modulation Type	Inhibition
Eltrombopag	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Eltrombopag inhibits the transportation of Tetraethylammonium by SLC22A1			[9]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Decitabine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Decitabine inhibits DNA methyltransferase, which then enhances Sorafenib's transportation via downregulating the hypermethylation in SLC22A1's promoter			[36]
Affected Drug/Substrate	Sorafenib	Modulation Type	Inducer
Cell System	Human embryonal rhabdomyosarcoma cells
Rosiglitazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Rosiglitazone increases the expression of SLC22A1			[37]
Regulation Mechanism	via enhancement of Peroxisome proliferator-activated receptor gamma (PPARG)			Transcription Factor Info
Cell System	Human vascular smooth muscle cells
Chenodeoxycholic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chenodeoxycholic acid inhibits the expression of SLC22A1			[38]
Regulation Mechanism	via the inhibition of Hepatocyte nuclear factor 4-alpha (HNF4A)			Transcription Factor Info
Cell System	Human adult hepatocellular carcinoma cells (Huh7)
Indomethacin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Indomethacin inhibits the activity of SLC22A1			[39]
Mefenamic Acid	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Mefenamic Acid inhibits the activity of SLC22A1			[39]
Urethane	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Urethane increases the expression of SLC22A1			[40]
Tretinoin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tretinoin increases the expression of SLC22A1			[41]
Crizotinib	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Crizotinib inhibits the activity of SLC22A1			[42]
Carvedilol	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Carvedilol inhibits the activity of SLC22A1			[43]
Dexamethasone	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dexamethasone induces the activity of SLC22A1			[44]
Insulin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Insulin induces the activity of SLC22A1			[45]
Pyrazinamide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Pyrazinamide inhibits the activity of SLC22A1			[46]
Itraconazole	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Itraconazole inhibits the activity of SLC22A1			[47]
Sparfloxacin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sparfloxacin inhibits the activity of SLC22A1			[48]
Atorvastatin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Atorvastatin inhibits the reaction SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium			[43]
Regulation Mechanism				Transcription Factor Info
Drug in Phase 2/3 Trial
MJ-13105	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bucindolol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Sodium butyrate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Butyrate inhibits histone deacetylase, which then enhances Sorafenib's transportation via increasing the histone acethylation level of SLC22A1			[36]
Affected Drug/Substrate	Sorafenib	Modulation Type	Inducer
Cell System	Human embryonal rhabdomyosarcoma cells
Drug in Phase 3 Trial
Anisodine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Anisodine inhibits the activity of SLC22A1 (IC50 = 12.9 microM)			[25]
Cell System	Human embryonic kidney 293 cells (HEK293)
Melagatran	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Melagatran inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Drug in Phase 2 Trial
YM155	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	YM155 inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 23.8 microM)			[5]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Gallopamil	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Gallopamil inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
2-Methoxyestradiol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	2-Methoxyestradiol inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Bisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Bisphenol A inhibits the activity of SLC22A1			[52]
Drug in Phase 1/2 Trial
Sodium taurocholate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sodium taurocholate inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Drug in Phase 1 Trial
Sodium arsenite	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Sodium arsenite inhibits the expression of SLC22A1			[53]
Drug in Preclinical Test
N-methylpyridinium	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	N-methylpyridinium inhibits the transportation of YM155 by SLC22A1 (IC50 = 30.4 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Epinephrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Epinephrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Beta-carboline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Beta-carboline inhibits the activity of SLC22A1			[54]
Discontinued Drug
Dizocilpine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dizocilpine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 80.5 microM)			[20]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Antiparasitics	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 7.4 microM)			[3]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Chinese hamster ovary (CHO) cells-OCT1
Acecainide	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Acecainide inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Investigative Drug
Tetraethylammonium	25 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 216 microM)			[1]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation2	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 469.7 microM)			[3]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Chinese hamster ovary (CHO) cells-OCT1
DT Modulation3	Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 158 microM)			[7]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation4	Tetraethylammonium inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 167 microM)			[8]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation5	Tetraethylammonium inhibits the transportation of Tetraethylammonium by SLC22A1			[9]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Decynium 22	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 21.9 microM)			[8]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Oocytes-OCT1
DT Modulation2	Decynium 22 inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 2.73 microM)			[4]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human cervical cancer cell line (Hela)-OCT1
Corticosterone	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Corticosterone inhibits the transportation of YM155 by SLC22A1 (IC50 = 8.89 microM)			[5]
Affected Drug/Substrate	YM155	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Corticosterone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Phencyclidine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phencyclidine inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 4.4 microM)			[20]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Androstenedione	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	4-Androstene-3-17-Dione inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Agmatine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Agmatine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Arcaine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Arcaine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Choline	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Choline inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Normetanephrine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Normetanephrine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Phenazone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenazone inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Beta-naphthoflavone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Beta-naphthoflavone inhibits the expression of SLC22A1			[50]
Drug Withdrawn
Phenformin	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phenformin inhibits the transportation of N-methylpyridinium by SLC22A1 (Ki = 13 microM)			[11]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Phenformin inhibits the transportation of Tetraethylammonium by SLC22A1 (Ki = 23 microM)			[11]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation3	Phenformin inhibits the activity of SLC22A1			[11]
Etilefrine	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A1 (IC50 = 447 microM)			[2]
Affected Drug/Substrate	N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Terfenadine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Terfenadine inhibits the transportation of 4-(4-(dimethylamino)styryl)-N-methylpyridinium by SLC22A1			[6]
Affected Drug/Substrate	4-(4-(dimethylamino)styryl)-N-methylpyridinium	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Natural Product
Fenamiphos	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fenamiphos inhibits the transportation of 4',6'-diamidino-2-phenylindole by SLC22A1 (IC50 = 27.5 microM)			[19]
Affected Drug/Substrate	4',6'-diamidino-2-phenylindole	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Fenamiphos inhibits the transportation of Dopamine by SLC22A1 (IC50 = 9.2 microM)			[19]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Phosmet	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Phosmet inhibits the transportation of 4',6'-diamidino-2-phenylindole by SLC22A1 (IC50 = 10.4 microM)			[19]
Affected Drug/Substrate	4',6'-diamidino-2-phenylindole	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
DT Modulation2	Phosmet inhibits the transportation of Dopamine by SLC22A1 (IC50 = 7.1 microM)			[19]
Affected Drug/Substrate	Dopamine	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Citreoverdine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citreoverdine inhibits the transportation of Organic cation by SLC22A1 (IC50 = 6.63 microM)			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
Dieldrin	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Dieldrin inhibits the transportation of Tetraethylammonium by SLC22A1 (IC50 = 0.9 microM)			[27]
Affected Drug/Substrate	Tetraethylammonium	Modulation Type	Inhibition
Cell System	Human hepatoma HepaRG cells-OCT1
Allethrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Allethrin inhibits the transportation of Verapamil by SLC22A1 (IC50 = 2.6 microM)			[28]
Affected Drug/Substrate	Verapamil	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Tetramethrin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetramethrin inhibits the transportation of Verapamil by SLC22A1 (IC50 = 4.9 microM)			[28]
Affected Drug/Substrate	Verapamil	Modulation Type	Inhibition
Cell System	Human embryonic kidney 293 cells (HEK293)-OCT1
Cigarette smoke condensate	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cigarette smoke condensate inhibits the transportation of Verapamil by SLC22A1 (IC50 = 12.5 microM)			[29]
Affected Drug/Substrate	Verapamil	Modulation Type	Inhibition
Cell System	Human hepatoma HepaRG cells-OCT1
Green tea	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Green tea inhibits the transportation of Metformin by SLC22A1			[34]
Affected Drug/Substrate	Metformin	Modulation Type	Inhibition
Cell System	Human enterocyte-like 2 cell (Caco-2)-OCT1
Hyperforin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Hyperforin inhibits the expression of SLC22A1			[49]
Regulation Mechanism	via enhancement of Nuclear receptor subfamily 1 group I member 2 (NR1I2)			Transcription Factor Info
Cell System	Human hepatoblastoma cells (HepG2)
Particulate Matter	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Particulate Matter inhibits the expression of SLC22A1			[51]
Methyleugenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Methyleugenol inhibits the expression of SLC22A1			[56]
Tobacco Smoke Pollution	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tobacco Smoke Pollution inhibits the expression of SLC22A1			[58]
Quercetin	4 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Imipramine inhibits the reaction SLC22A1 protein results in increased uptake of Quercetin			[85]
Regulation Mechanism				Transcription Factor Info
DT Modulation2	Quinidine inhibits the reaction SLC22A1 protein results in increased uptake of Quercetin			[85]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	SLC22A1 protein results in increased uptake of Quercetin			[85]
Regulation Mechanism				Transcription Factor Info
DT Modulation4	Trimethoprim inhibits the reaction SLC22A1 protein results in increased uptake of Quercetin			[85]
Regulation Mechanism				Transcription Factor Info
Environmental toxicant
Tetrabromobisphenol A	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Tetrabromobisphenol A inhibits the activity of SLC22A1			[52]
Polychlorinated dibenzodioxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Polychlorinated dibenzodioxin inhibits the expression of SLC22A1			[29]
Mycotoxins
Aflatoxin B1	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Aflatoxin B1 inhibits the transportation of Organic cation by SLC22A1 (IC50 = 64.4 microM)			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
DT Modulation2	Aflatoxin B1 affects the expression of SLC22A1 protein			[73]
Regulation Mechanism				Transcription Factor Info
DT Modulation3	Aflatoxin B1 results in decreased expression of SLC22A1 mRNA			[74]
Regulation Mechanism				Transcription Factor Info
Alpha-zearalenol	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Alpha-zearalenol inhibits the transportation of Organic cation by SLC22A1 (IC50 = 1.7 microM)			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
Citrioveridine	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Citrioveridine inhibits the transportation of Organic cation by SLC22A1 (IC50 = 6.63 microM)			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
Cyclopiazonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Cyclopiazonic acid inhibits the transportation of Organic cation by SLC22A1 (IC50 > 1000 microM)			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
Fumonisin B1	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Fumonisin B1 inhibits the transportation of Organic cation by SLC22A1 (IC50 > 1000 microM)			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
Patulin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Patulin inhibits the transportation of Organic cation by SLC22A1			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
Gliotoxin	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Gliotoxin inhibits the transportation of Organic cation by SLC22A1 (IC50 = 584 microM)			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
Zearalenone	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Zearalenone inhibits the transportation of Organic cation by SLC22A1 (IC50 = 0.62 microM)			[26]
Affected Drug/Substrate	Organic cation	Modulation Type	Inhibition
Cell System	The Proximal Tubule (S2) Cells-OCT1
Carcinogen
Benzo(a)pyrene	3 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Benzo(a)pyrene inhibits the expression of SLC22A1			[56]
Pesticide/Insecticide
Endosulfan	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Endosulfan inhibits the expression of SLC22A1			[27]
Heptachlor	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Heptachlor inhibits the activity of SLC22A1			[27]
Imidacloprid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Imidacloprid increases the activity of SLC22A1			[55]
imidacloprid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	imidacloprid results in increased activity of SLC22A1 protein			[55]
Regulation Mechanism				Transcription Factor Info
Health and Environmental Toxicant
DT Modulation1	Endosulfan results in decreased activity of SLC22A1 protein			[27]
Regulation Mechanism				Transcription Factor Info
Chlordan	2 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Chlordan inhibits the activity of SLC22A1			[27]
Perfluorooctane sulfonic acid	1 DT Activity Modulations Related to This Exogenous Factor		Click to Show/Hide the Full List
DT Modulation1	Perfluorooctane sulfonic acid inhibits the expression of SLC22A1			[57]

References
1	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
2	Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
3	Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
4	Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61.
5	Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
6	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008 Oct 9;51(19):5932-42.
7	Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther. 2000 Mar;292(3):1146-52.
8	Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31.
9	Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
10	Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J. 2011 Dec;11(6):400-11.
11	Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica. 2007 Jun;37(6):618-34.
12	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1). J Med Chem. 2017 Apr 13;60(7):2685-2696.
13	Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
14	Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008 Jun;57(6):1463-9.
15	Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol. 2003 Mar;63(3):489-98.
16	Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011 Jul 17;43(4):297-307.
17	Interaction between nicotine and MPTP/MPP+ in rat brain endothelial cells. Life Sci. 2007 Aug 2;81(8):664-72.
18	Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21.
19	Interactions of organophosphorus pesticides with solute carrier (SLC) drug transporters. Xenobiotica. 2019 Mar;49(3):363-374.
20	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
21	Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008 Aug;36(8):1616-23.
22	Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 2000 Mar;28(3):329-34.
23	Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the liver and systemic bioavailability. Biochem Biophys Res Commun. 2001 Nov 23;289(1):130-6.
24	Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011 Mar;89(3):416-21.
25	An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families. Chin J Nat Med. 2019 Jul;17(7):490-497.
26	Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci. 2008 Mar;106(3):435-43.
27	Regulation of hepatic drug transporter activity and expression by organochlorine pesticides. J Biochem Mol Toxicol. 2014 Mar;28(3):119-28.
28	Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin. PLoS One. 2017 Jan 18;12(1):e0169480.
29	Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate. Toxicology. 2016 Jul 1;363-364:58-71.
30	Modulation of organic cation transport and lipid fluidity by benzyl alcohol in rat renal brush-border membranes. Pharm Res. 1996 Jul;13(7):1069-72.
31	In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013 Feb;41(2):353-61.
32	Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82.
33	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
34	Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein. PLoS One. 2015 Oct 1;10(10):e0139370.
35	Salbutamol: how does it enter smooth muscle cells? Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):541-6.
36	Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. Hepatology. 2019 Apr 10.
37	Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ Res. 2003 Aug 22;93(4):e38-47.
38	The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther. 2006 May;317(2):778-85.
39	Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
40	Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
41	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423.
42	KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG02908)
43	Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol. 2011 Jun;178(6):2547-59.
44	Study of the effect of the low dosage endotoxin damage on the expression of the organic cation transporter (OCT1) mRNA in hepatocytes. Zhonghua Gan Zang Bing Za Zhi. 2004 Apr;12(4):234-6.
45	Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice. Drug Metab Pharmacokinet. 2010;25(4):392-7.
46	Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6558-6567.
47	Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. Drug Metab Dispos. 2016 Mar;44(3):453-9.
48	Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials. Antimicrob Agents Chemother. 2013 Jun;57(6):2705-11.
49	The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. Br J Pharmacol. 2016 May;173(10):1703-15.
50	Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
51	Regulation of human hepatic drug transporter activity and expression by diesel exhaust particle extract. PLoS One. 2015 Mar 24;10(3):e0121232.
52	Inhibition of SLC drug transporter activities by environmental bisphenols. Toxicol In Vitro. 2017 Apr;40:34-44.
53	Cellular and Molecular Effects of Prolonged Low-Level Sodium Arsenite Exposure on Human Hepatic HepaRG Cells. Toxicol Sci. 2018 Apr 1;162(2):676-687.
54	Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines. Toxicol In Vitro. 2019 Feb;54:10-22.
55	Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379.
56	Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
57	Perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorononanoic acid (PFNA) increase triglyceride levels and decrease cholesterogenic gene expression in human HepaRG liver cells. Arch Toxicol. 2020 Sep;94(9):3137-3155.
58	Comparative biological impacts of an aerosol from carbon-heated tobacco and smoke from cigarettes on human respiratory epithelial cultures: A systems toxicology assessment. Food Chem Toxicol. 2018 May;115:109-126.
59	Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol. 2009;296(6):F1504-13.
60	Expression of Organic Anion Transporting Polypeptide 1A2 in Red Blood Cells and Its Potential Impact on Antimalarial Therapy. Drug Metab Dispos. 2016;44(10):1562-8.
61	Effects of diosmetin on nine cytochrome P450 isoforms, UGTs and three drug transporters in vitro. Toxicol Appl Pharmacol. 2017;334:1-7.
62	Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity. Toxicology. 2013;311(3):225-30.
63	C-myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells. Mol Pharm. 2009;6(2):627-33.
64	Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet. 1999;63(Pt 6):473-82.
65	Inhibition of hepatic uptake transporters by flavonoids. Eur J Pharm Sci. 2012;46(1-2):79-85.
66	Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
67	Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
68	Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity. Toxicology. 2014;322:34-42.
69	Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters. J Ocul Pharmacol Ther. 2015;31(4):248-55.
70	Integration of transcriptomics, proteomics and metabolomics data to reveal the biological mechanisms of abrin injury in human lung epithelial cells. Toxicol Lett. 2019;312:1-10.
71	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
72	Testing in vitro tools for the prediction of cholestatic liver injury induced by non-pharmaceutical chemicals. Food Chem Toxicol. 2021;152:112165.
73	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
74	Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 2016 Mar 28;350-352:31-9.
75	Integration of transcriptomic, proteomic and metabolomic data to reveal the biological mechanisms of AAI injury in renal epithelial cells. Toxicol In Vitro. 2021;70:105054.
76	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017;8(1):1369-1391.
77	Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121.
78	Identification of potential target genes of ROR-alpha in THP1 and HUVEC cell lines. Exp Cell Res. 2017;353(1):6-15.
79	Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
80	Dataset on transcriptomic profiling of cholestatic liver injury induced by food additives and a cosmetic ingredient. Data Brief. 2021;38:107373.
81	Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4a upregulation in primary human hepatocytes. Pharmacol Rep. 2013;65(5):1322-35.
82	The effect of folate status on the uptake of physiologically relevant compounds by Caco-2 cells. Eur J Pharmacol. 2010 Aug 25;640(1-3):29-37.
83	DNA methylation alterations in response to pesticide exposure in vitro. Environ Mol Mutagen. 2012;53(7):542-9.
84	Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. Drug Metab Dispos. 2014;42(11):1780-4.
85	Organic anion transporting polypeptides and organic cation transporter 1 contribute to the cellular uptake of the flavonoid quercetin. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(9):883-91.
86	Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009;329(1):252-61.
87	Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1. Biopharm Drug Dispos. 2018;39(9):411-419.
88	OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes. 2011;60(1):168-76.
89	A multi-omics approach to elucidate okadaic acid-induced changes in human HepaRG hepatocarcinoma cells. Arch Toxicol. 2024;98(9):2919-2935.
90	Ozone exposure and blood transcriptome: A randomized, controlled, crossover trial among healthy adults. Environ Int. 2022;163:107242.
91	High-Throughput Transcriptomic Analysis of Human Primary Hepatocyte Spheroids Exposed to Per- and Polyfluoroalkyl Substances as a Platform for Relative Potency Characterization. Toxicol Sci. 2021 May 27;181(2):199-214.
92	Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One. 2009;4(8):e6796.
93	The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine inhibits lipopolysaccharide-induced inflammation transcriptomic pathways and cytokine secretion in a macrophage cell model. Toxicol In Vitro. 2022;84:105429.
94	Transcriptional responses of human aortic endothelial cells to nanoconstructs used in biomedical applications. Mol Pharm. 2013;10(8):3242-52.
95	High-Throughput Transcriptomics of Nontumorigenic Breast Cells Exposed to Environmentally Relevant Chemicals. Environ Health Perspect. 2024;132(4):47002.
96	Polarized location of SLC and ABC drug transporters in monolayer-cultured human hepatocytes. Toxicol In Vitro. 2015;29(5):938-46.
97	Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
98	Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
99	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.

Detail Information of Exogenous Modulation

Visitor Map

Correspondence